Navigation Links
Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
Date:7/11/2011

PARIS, July 11, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc. (NYSE/TSX: VRX) ("Valeant"), for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.

(Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)

Dermik has a significant presence in the medical dermatology market in the United States and Canada with a strong field force and well-known brands. Dermik's portfolio includes leading therapeutic and aesthetic dermatology brands such as BenzaClin® for the treatment of acne, Carac® for the treatment of keratoses and Sculptra®, a facial injectable for the correction of facial wrinkles and folds.

The scope of this transaction includes Dermik assets, which consist of an aesthetic and therapeutic business in the United States and Canada, as well as an aesthetic business around the world with sales of US $206 million in 2010. Also included in the scope is Sanofi's Laval, Canada site, which includes Dermik's manufacturing facility.  Sanofi's Canadian affiliate, sanofi-aventis Canada, will maintain its operations in greater Montreal.

Sanofi decided to divest its dermatology business with the intention to further concentrate on its growth platforms. Sanofi believes that Dermik will benefit from being part of a larger dermatology business.

Commenting on the agreement, Christopher A. Viehbacher, Chief Executive Officer of Sanofi, said: "Our strategy is based upon our growth platforms and innovation. This divestiture allows us to rationalize our portfolio and improve focus on our core businesses. Our manufacturing operations in Laval and our field operations teams will
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sanofi Enters Into Research Collaboration with Weill Cornell Medical College to Discover New Treatments for Tuberculosis
2. Sanofi Pasteur Commends Winners of International BioGENEius Challenge
3. Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen
4. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
5. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
6. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
7. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
8. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
9. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
10. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
11. Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... World ... Fresh Plus Diaper, a baby invention that makes parenthood less tiring without sacrificing ... reach a market value of USD 52.2 billion in 2017," says Scott Cooper, ...
(Date:6/29/2015)... ... June 29, 2015 , ... People across the country give their coworkers and families gifts ... our culture. , But, how often do coworkers donate “life” to the husband of ... one. , “Dawna (Wright-Thompson) told me her husband was on a donor list,” ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... With Urgent ... announces a partnership with the American Board of Urgent Care Medicine and the Medical ... Category 1 Credit™ to Urgent Care physicians and health care professionals. , According to ...
(Date:6/29/2015)... Valley, CA (PRWEB) , ... June 29, 2015 , ... ... treatments designed to lift and tighten sagging skin. Ulthera is a special treatment that ... Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is highly targeted ...
(Date:6/29/2015)... ... 2015 , ... New research released today at the National ... U.S. state and local governments have implemented Next Generation 9-1-1 (NG9-1-1) systems, and ... , “Mobile phones have surpassed land lines as the primary mode for calling ...
Breaking Medicine News(10 mins):Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4
... LES ULIS, France, September 19 Following the,successful ... made it,possible to raise EUR7.6 million, Quantel signed ... company Wavelight AG to acquire,WaveLight Aesthetic GmbH, its ... agreement The acquisition price includes a EUR4.6 ...
... Sept. 19 If you,ve been experiencing watery,eyes and ... the,rise in the U.S., with an estimated 50 million ... to the tune of 3 billion,dollars a year, often ... say in-vitro blood tests, the latest generation of,allergy tests, ...
... with mice might lead to treatments for diseases such as ... U.S. researchers say they,ve successfully reprogrammed adult stem cells from ... cell types, including functional blood vessels, contractile cardiac tissue, and ... adult testes stem cells from humans, they may offer a ...
... Easily accessed and plentiful, adult stem cells found in a ... wide range of tissue types to help him fight disease ... cells. , That,s the promise of a breakthrough study in ... in New York City, who report their findings in the ...
... Americans will,have access to high-quality, evidence-based care for ... U.S. Senate. The,"Mental Health Parity Act of 2007" ... to provide parity with respect to all financial,requirements ... ) "AHIP applauds the Senate for ...
... Sept. 19 When Michael Murphy of,Seymour, Iowa, was ... the halftime of the September 15th Iowa vs. Iowa ... "Join the Ride, Iowa",raffle. The Iowa Farm Bureau donated ... and raffle (tickets were $10 each) to the American,Lung ...
Cached Medicine News:Health News:QUANTEL Finalizes the Acquisition of WaveLight Aesthetic GmbH 2Health News:Stem Cells From Testes Produce Wide Range of Tissue Types 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 4Health News:Renewable Fuel Chopper Raffle Nets $113,000 for American Lung Association Clean Air Choice Program 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: